Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10743911 | Maturitas | 2005 | 6 Pages |
Abstract
Objectives: A prospective, randomized, open-label study was conducted to evaluate effects on mammographic density in postmenopausal and late perimenopausal women receiving continuous combined or sequential combined hormone replacement therapy (HRT). Methods: The subjects were randomized to treatment with low-dose continuous combined HRT containing 1 mg 17β-estradiol plus 0.5 mg norethisterone acetate (Activelle®) or a sequential combined HRT regimen consisting of 0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days (Presomen®). Mammograms were obtained at baseline and after 9 cycles (each 28 days) of treatment. Results: The majority of women (approximately two-thirds in each treatment group) had no changes in mammographic breast density between baseline and the final study visit. There were no marked differences between treatment groups. Approximately 20% of women in both groups had a slight increase in mammographic density. Only 10-14% of women in both groups had a pronounced increase in mammographic density. The analyses of the degree of change showed no remarkable differences between treatments. Conclusion: These results indicate that the increase in mammographic density with a low-dose continuous combined HRT regimen is no greater than that with a sequential combined HRT regimen. The type of progestogen does not have an impact on the extent of mammographic density changes.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Hans Junkermann, Thomas von Holst, Eva Lang, Viatcheslav Rakov,